✨ Free AI Report
Astellas Pharma Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Astellas Pharma Inc.
Company Research

Astellas Pharma Inc.: Business Overview, Financials & Competitive Analysis

Astellas Pharma Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Trading at 56.1% below estimate of fair value, but faces long-term revenue headwinds from patent expirations and competitive pressures. The company has shifted back into profit on a trailing twelve month basis with net income of ¥322.9b compared to a loss of ¥57.4b a year ago, supported by three.

What is Astellas Pharma Inc.'s industry? Astellas Pharma Inc. (astellas.com) operates in Pharmaceutical Manufacturing - General. AskCyborg classifies Astellas Pharma Inc. under Pharmaceutical Manufacturing - General in its company registry.

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company is a specialty international pharmaceutical company focused on accelerating the discovery, dev...

6/ 10Solid

Cyborg Score thesis

Trading at 56.1% below estimate of fair value, but faces long-term revenue headwinds from patent expirations and competitive...

Read the full analyst-debate transcript →
Industry Pharmaceutical Manufacturing - General
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 26, 2026
AI-Generated Research
30+ Page Report

Get the Latest Astellas Pharma Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Astellas Pharma Inc.

AskCyborg analysts argue the bull and bear cases for Astellas Pharma Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Astellas Pharma Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Astellas Pharma Inc. Overview

Pro stress-test →

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company is a specialty international pharmaceutical company focused on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases.

Strategic Profile

Pro stress-test →

The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Astellas is experiencing strong global sales trends of XTANDI for prostate cancer and BETANIS/MYRBETRIQ/BETMIGA for overactive bladder.

Competitive Landscape

Pro stress-test →

One of Astellas Pharma's 64 competitors is Novartis, a Corporation company based in Basel, Switzerland. Loss of exclusivity for major drugs and persistent R&D challenges threaten future revenue stability, while pricing pressures, regulatory risks, and supply chain complexities increase margin volatility across key global markets.

Industry Context

Astellas Pharma Inc. operates in Pharmaceutical Manufacturing - General.

Key facts

Founded: 1923 · Headquarters: Chuo, Japan · Revenue: $13.4B · Market cap: $28.9B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Astellas Pharma Inc..

  • Strong global sales momentum in flagship drugs XTANDI and BETANIS/MYRBETRIQ/BETMIGA driving upward forecast revisions
  • Trading on trailing P/E of 13.4x versus peer average of 19.5x and industry average of 16.5x, suggesting potential valuation discount
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced upward revisions to consolidated financial forecast for FY2025 ending March 31, 2026
  • Q3 2026Posted revenue of ¥571.2 billion and basic EPS of ¥56.04
  • +1 moreTrack every material event for Astellas Pharma Inc. as it happens. Explore monitoring →
Get alerted when Astellas Pharma Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gilenya/FingolimodImmunology and rare disease focus→PharmacovigilanceOncology and diagnostics leader→Oncology PortfolioLarge cap diversified pharma→Specialty PharmaNeurology and immunology specialist→

Compare Astellas Pharma Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Astellas Pharma Inc. operates in Pharmaceutical Manufacturing - General. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Manufacturing - General research →
NEW · MCP server

Ask your AI assistant about Astellas Pharma Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Astellas Pharma Inc. and its top competitor on Cyborg Score”
“What did Astellas Pharma Inc. do this quarter?”
“Is Astellas Pharma Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Astellas Pharma Inc. do?+
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company is a specialty international pharmaceutical company focused on accelerating the discovery, dev...
What is Astellas Pharma Inc.'s Cyborg Score?+
Astellas Pharma Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Astellas Pharma Inc.'s main competitors?+
Named competitors include Gilenya/Fingolimod, Pharmacovigilance, Oncology Portfolio, Specialty Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Astellas Pharma Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Astellas Pharma Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Astellas Pharma Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.